Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second consecutive year in 2022, even as Pfizer marched on with its spending spree. Their collective expenditure – $157 billion – might be the smallest since 2018, but it's still a…
Report library
Biopharma and Medtech Review 2022
To even the most optimistic soul, 2022 was not a vintage year for the world of biopharma and medtech. Public markets continued their downward trajectory and many…
Obesity matters for drug developers
Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting…
Five questions to ask when reviewing your pipeline
Pharma’s R&D pipeline is its lifeblood. The industry-wide pipeline is today worth a staggering $1.4 trillion. Yet, like many others, you may find that getting R&D…
JP Morgan Healthcare Conference 2023
The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…
Evaluate Vantage 2023 Preview Infographic
The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…
ASH 2022
As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…
The Billion Dollar Question: Are payer perspectives part of your strategy?
There are many factors that impact the success of a new therapy. Efficacy, differentiation, market size, and of course, cost. For this last point, the importance of…
Evaluate Vantage 2023 Preview
After a tough year for many in biopharma, what’s the outlook for 2023? Evaluate Vantage’s preview sets out the projects waiting in the wings that could drive some…
ASH 2022 Preview
The 2022 ASH Annual Meeting is due to take place on December 10-13 in New Orleans, Louisiana. Get yourself prepared with Evaluate Vantage's preview of the…
How to spot blockbuster potential?
In 2021, the pharma industry invested over $600 billion in R&D, M&A and licensing in search of the next life-changing and market-leading products. With a patent…
